内容提示: Rituximab: Mechanism of ActionGeorge J. WeinerRituximab is a mainstay in the therapy for a broad variety of B-cell malignancies. Despite itsundeniable therapeutic value, we still do not fully understand the mechanisms of action responsiblefor rituximab’s anti-tumor effects. Direct ...
Drug insight: the mechanism of action of rituximab in autoimmune disease: the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007;3:86–95.Ronald PTaylor, Margaret ALindorfer. (2007) Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy ...
Rituximab (Rituxan; Genentech, Inc, South San Francisco, CA, and IDEC Pharmaceuticals, San Diego, CA)-mediated killing of CD20-positive tumor cells is likely caused by a combination of immune-mediated effects including complement-mediated lysis and antibody-dependent cell-mediated cytotoxicity and dir...
The Fab region gives rituximab its specificity for CD20, while the Fc region interacts with cell surface receptors to activate the immune system, leading to the depletion of circulating B lymphocytes 6. In regards to the mechanism of action in rheumatoid arthritis (RA), B-cells are thought to...
RituximabCD20MechanismResistanceComplementB‐cell non‐Hodgkin's lymphomaRituximab, a genetically engineered chimeric monoclonal antibody specifically binding to CD20, was the first antibody approved by the U.S. Food and Drug Administration for the treatment of cancer. Rituximab significantly improves ...
Rituximab The risk or severity of neutropenia can be increased when Trastuzumab is combined with Rituximab. Roflumilast Roflumilast may increase the immunosuppressive activities of Trastuzumab. Romosozumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Romosozuma...
Rituximab: mechanism of action. 来自 掌桥科研 喜欢 0 阅读量: 118 作者: GJ Weiner 摘要: Rituximab is a mainstay in the therapy for a broad variety of B-cell malignancies. Despite its undeniable therapeutic value, we still do not fully understand the mechanisms of action responsible for ...
10. Transportation of COVID-19 mRNA vaccines and its effect on properties 11. Can the genetic content of COVID-19 mRNA vaccines integrates into the human genome? 12. The impact of mRNA vaccines on the next generation of humans 13. COVID-19 booster doses 14. Increased risk of autoimmune ...
(rituximab and ofatumumab) and type II (HuMab-11B8) CD20 antibodies in a peritoneal, syngeneic, mouse model with EL4-CD20 cells using low and high tumor burden.ResultsInterestingly, we observed striking differences in the in vivo mechanism of action of CD20 antibodies dependent on tumor load. ...
Diffuse large B-cell lymphoma (DLBCL) represents a prevalent malignant tumor, with approximately 40% of patients encountering treatment challenges or relapse attributed to rituximab resistance, primarily due to diminished or absent CD20 expression. Our prior research identified PDK4 as a key driver of...